Catalyst overview
Research summary
This catalyst tracks a Phase 2a data readout for Bempikibart (ADX-914) in Alopecia areata. The expected timing is based on the latest available company guidance and may change.
SIGNAL-AA trial. 5/9/24- Enrollment completed. 12/10/24- Topline data reported. 8/6/25- Dosed the 1st patients in Part B & OLE. 10/21/25– Enrollment completed. Topline data in mid-2026. 11/13/25:- Part B enrollment confirmed at 33 patients with emerging activity; Part A open-label extension dosing ongoing; mid-2026 topline. 03/10/26:- SIGNAL-AA Part B enrollment reiterated; 36-week topline mid-2026; Part A OLE ongoing; emerging activity described. 05/05/26:- 36-week Part B topline on track mid-2026. First Part B OLE patient dosed; Part A OLE completed. 07/13/26:- Positive 36-week Part B topline reported. Registration-directed program planned in H1 2027. 08/05/26:- Meeting data in H2 2026. Ph3 starts H1 2027. OLE data H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.